NEW YORK (GenomeWeb News) - NextGen Sciences said today that it will now offer protein biomarker services, including assay development and validation, and that it has named Mike Pisano, the former head of Protein Research Services, to be CEO of the company.
NextGen said its biomarker services are supported by the proteomics know-how that it acquired when it bought PRS in 2006, and by its investments into technologies such as ThermoFisher’s OrbiTrap and its triple quad mass spectrometers.
The new services include monitoring and verification of protein biomarkers from pre-clinical and clinical samples, and identification of putative protein biomarkers and proteins of interest, NextGen said.
Pisano said the company already is “working with a number of major customers to develop robust, accurate and precise assays to meet the needs of their clinical biomarker projects.”